Located in San Diego, California, OncoSec has quickly made a name for themselves as a developer of novel ElectroOncology therapies that combine their proprietary electroporation delivery technology with a chemotherapeutic or DNA-based immunotherapeutics. Today, OncoSec took a major step towards accelerating the development of its cancer therapeutic delivery device with the appointment of Brian McCluskey as their Executive Director of Engineering.
McCluskey is a renowned name in the sector and brings over 30 years of electrical engineering experience with him. For the last 20 years, McCluskey has developed software and hardware devices used for medical and research purposes.
Leading the way at OncoSec is Punit Dhillon whom serves as the company’s President and CEO. Commenting on the addition of McCluskey, Dhillon stated, “We are pleased that Brian will join our management team. He brings a proven track record of medical device design and technical leadership experience, with the ability to design, manage and coordinate the development of medical devices from concept to production. Brian will be instrumental in developing OncoSec’s next generation OMS products.”
Currently, OncoSec is trading in the $1.02 range. To learn more about this press release or the company as a whole, visit the company website at: www.oncosec.com